Ablynx Reports Detailed Positive Phase Ib Results for Its Anti- Thrombotic Nanobody(R) ALX-0081

GHENT, BELGIUM, Mar 30 (MARKET WIRE) --
Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and
development of Nanobodies(R), a novel class of antibody-derived
therapeutic proteins, announced today the detailed results from the Phase
Ib study of its anti- thrombotic ALX-0081. The primary endpoint,
demonstrating the complete inhibition of the target protein as measured
by a specific biomarker, was reached in December 2008. These positive
detailed data support the progression of ALX-0081 into Phase II testing,
expected to commence in Q3 2009.

During the period May to December 2008, the study recruited a total of 25
patients with stable angina undergoing an elective percutaneous coronary
intervention (PCI) procedure. Total daily doses of ALX- 0081 ranging from
2 to 18 mg were added to a standard anti- thrombotic regimen including
aspirin, heparin and Plavix(R). The double blind study randomized
patients in a 3:1 ratio to either active study drug (ALX-0081) or
placebo, resulting in a total of 19 patients receiving ALX-0081
intravenous infusions and six patients receiving placebo. The biological
effect of ALX-0081 was determined via a biomarker, indicating the
complete inhibition of von Willebrand Factor (vWF) and its mediated
effect on platelet aggregation and clotting in coronary arteries.

The study included a single dose and a multiple dose escalation. Single
doses were escalated until the required biological effect (complete
biomarker inhibition for at least six hours in all ALX- 0081 treated
patients) was confirmed. The subsequent multiple dosing was aimed to
ensure complete inhibition of the biomarker for at least 24 hours. All
patients who received ALX-0081 showed complete inhibition of the
biomarker with a duration of 4 to 18 hours in the single dose group and
for at least 24 hours in the multiple dose group. In all patients, the
pharmacological markers returned to normal 12-36 hours after dosing.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.

Copyright
Copyright Hugin AS 2009. All rights reserved.

For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, Dr John McIntyre
t: +44 (0)20 7866 7857
e: Email Contact

Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: Email Contact

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-